Protagonist Therapeutics Inc (PTGX NASDAQ) stock market data APIs
$59.0375
0.72(1.2%)
as of September 17, 2025
Try our APIs with
free plan!
Protagonist Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Prev. Close
59.0375
Open
59.7562
High
60.9251
Low
59.246
52 wk Range
33.31-61.89
Market Cap
3 645 M
P/E Ratio
80.2603
Shares Outstanding
62 211 K
Revenue
209 M
EPS
-0.55
Beta
2.221
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Protagonist Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Protagonist Therapeutics Inc data using free add-ons & libraries
Get Protagonist Therapeutics Inc Fundamental Data
Protagonist Therapeutics Inc Fundamental data includes:
- Net Revenue: 209 M
- EBITDA: 24 868 K
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-06
- EPS/Forecast: -0.58
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Protagonist Therapeutics Inc News
New
Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory
We came across a bullish thesis on Protagonist Therapeutics, Inc. on BiotechBonanza’s Substack by AnotherBio. In this article, we will summarize the bulls’ thesis on PTGX. Protagonist Therapeutics...
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025
NEWARK, CALIFORNIA / ACCESS Newswire / September 15, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that data from the Phase 2b ANTHEM-UC study with icotrokinra in ul...
Exploring High Growth Tech Stocks in the US Market September 2025
As of September 2025, the U.S. stock market is witnessing a mixed performance with the tech-heavy Nasdaq Composite reaching record highs, driven by strong performances from major tech companies like T...
JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra
Johnson & Johnson JNJ has submitted a regulatory filing to the European Medicines Agency (EMA) to seek approval for its investigational oral peptide, icotrokinra, to treat moderate-to-severe plaque ps...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
